Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 3, 2014, Pages 1269-1276

  Taketani, Yukako ^a,b   Yamagishi, Reiko ^a   Fujishiro, Takashi ^a,c   Igarashi, Masaki ^a   Sakata, Rei ^a,d   Aihara, Makoto ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Asahi Central Hospital   (Japan)

^c Saitama Sekijuji Hospital   (Japan)

^d Tokyo Metropolitan Institute of Gerontology   (Japan)

Author keywords

Deepening of the upper eyelid sulcus; FP receptor; Lipids; Prostaglandins

Indexed keywords

BIMATOPROST; LATANOPROST; PROSTAGLANDIN F2 ALPHA; PROSTANOID RECEPTOR; TAFLUPROST; TRAVOPROST; UNOPROSTONE;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL STIMULATION; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROADIPOCYTE;

DEEPENING OF THE UPPER EYELID SULCUS; FP RECEPTOR; LIPIDS; PROSTAGLANDINS;

ADIPOCYTES; ADIPOGENESIS; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EYELIDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORBIT; ORBITAL DISEASES; PROSTAGLANDINS, SYNTHETIC; RECEPTORS, PROSTAGLANDIN;

EID: 84895757239     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12589     Document Type: Article

References (39)

1. Ota T, Aihara M, Narumiya S, Araie M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptordeficient mice. Invest Ophthalmol Vis Sci. 2005;46:4159-4163.
2. Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013;8: e61638.
3. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg. 2008;24:302-307.
4. Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011;55:22-27.
5. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81:574-577.
6. Tappeiner C, Perren B, Iliev ME, Frueh BE, Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost-can bimatoprost cause enophthalmos? [in German]. Klin Monbl Augenheilkd. 2008;225:443-445.
7. Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther. 2009;25:471-472.
8. Inoue K, Shiokawa M, Wakakura M, Tomita G. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013;22:626-631.
9. Ung T, Currie ZI. Periocular changes following long-term administration of latanoprost 0.005%. Ophthal Plast Reconstr Surg. 2012;28:e42-e44.
10. Aihara M, Shirato S, Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn J Ophthalmol. 2011;55:600-604.
11. Sakata R, Shirato S, Miyata K, Aihara M. Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost. Jpn J Ophthalmol. 2013;57:179-184.
12. van der Valk R, Webers CA, Lumley T, Hendrikse F, Prins MH, Schouten JS. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol. 2009;62:1279-1283.
13. Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009;116: 1243-1249.
14. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17:667-673.
15. Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115:1117-1122. e1.
16. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177-1185.
17. Jayaprakasam A, Ghazi-Nouri S. Periorbital fat atrophy-an unfamiliar side effect of prostaglandin analogues. Orbit. 2010; 29:357-359.
18. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-2556.
19. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104:531-543.
20. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med. 2004;10:355-361.
21. Fujimori K, Aritake K, Urade Y. A novel pathway to enhance adipocyte differentiation of 3T3-L1 cells by up-regulation of lipocalin-type prostaglandin D synthase mediated by liver X receptor-activated sterol regulatory element-binding protein-1c. J Biol Chem. 2007;282:18458-18466.
22. Miller CW, Casimir DA, Ntambi JM. The mechanism of inhibition of 3T3-L1 preadipocyte differentiation by prostaglandin F2alpha. Endocrinology. 1996;137:5641-5650.
23. Seibold LK, Ammar DA, Kahook MY. Acute effects of glaucoma medications and benzalkonium chloride on pre-adipocyte proliferation and adipocyte cytotoxicity in vitro. Curr Eye Res. 2013;38:70-74.
24. Choi HY, Lee JE, Lee JW, Park HJ, Lee JE, Jung JH. In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes. J Ocul Pharmacol Ther. 2012;28:146-152.
25. Sugihara H, Yonemitsu N, Miyabara S, Toda S. Proliferation of unilocular fat cells in the primary culture. J Lipid Res. 1987;28: 1038-1045.
26. Yagi K, Kondo D, Okazaki Y, Kano K. A novel preadipocyte cell line established from mouse adult mature adipocytes. Biochem Biophys Res Commun. 2004;321:967-974.
27. Rodbell M. Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem. 1964;239:375-380.
28. Sawaya S, Koyama Y, Nagayasu A, et al. Effect of prolyl hyrdoxproline on the differentiation of mouse 3T3L-1 preadipocytes in vitro. J Rakuno Gakuen Univ. 2008;33:13-18.
29. Liang Y, Woodward DF, Guzman VM, et al. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol. 2008;154:1079-1093.
30. Thieme H, Stumpff F, Ottlecz A, Percicot CL, Lambrou GN, Wiederholt M. Mechanisms of action of unoprostone on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2001;42:3193-3201.
31. Cuppoletti J, Malinowska DH, Tewari KP, Chakrabarti J, Ueno R. Cellular and molecular effects of unoprostone as a BK channel activator. Biochim Biophys Acta. 2007;1768:1083-1092.
32. Green H, Kehinde O. An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. Cell. 1975;5:19-27.
33. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19:501-515.
34. Sharif NA, Crider JY, Husain S, Kaddour-Djebbar I, Ansari HR, Abdel-Latif AA. Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2{thorn} mobilization and MAP kinase activation. J Ocul Pharmacol Ther. 2003;19:437-455.
35. Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:768-776.
36. Smid SD. Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: closer look at the agonist properties of bimatoprost and the prostamides. Clin Ophthalmol. 2009;3:663-670.
37. Hellberg MR, Ke TL, Haggard K, Klimko PG, Dean TR, Graff G. The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2α by human and rabbit ocular tissue. J Ocul Pharmacol Ther. 2003;19:97-103.
38. Ichhpujani P, Katz LJ, Hollo G, et al. Comparison of human ocular distribution of bimatoprost and latanoprost. J Ocul Pharmacol Ther. 2012;28:134-145.
39. Faulkner R, Sharif NA, Orr S, et al. Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of lumigan or travatan. J Ocul Pharmacol Ther. 2010;26:147-156.